Regen BioPharma(OTC) RGBPP

Regen BioPharma, Inc. is focused on advancing regenerative medicine solutions in the United States. The company is engaged in the development of small molecules that modulate NR2F6, targeting cancer treatments and autoimmune conditions.

Products and Services

• Development of small molecules for cancer treatment
• Therapeutic approaches for autoimmune conditions
• Research in regenerative medicine

Growth Outlook

• Product pipeline is in early developmental phases
• Potential for significant market impact in regenerative medicine
• Focus on innovative therapies may attract strategic partnerships

Financial Highlights

• Recent quarterly revenue of 59,065 demonstrates consistent performance
• Net income of 991,927 in Q2 2026 indicates potential for profitability
• Cash and cash equivalents at 271 show liquidity challenges

Regen BioPharma, Inc. operates in the biotechnology sector, with a mission to innovate in the field of regenerative medicine. The company’s focus on small molecules that modulate NR2F6 positions it uniquely within the industry, targeting both cancer and autoimmune diseases. Despite being in the early stages of product development, the potential for significant market impact exists, particularly as the demand for advanced therapeutic solutions continues to grow. Recent financial performance shows a quarterly revenue of 59,065, indicating a stable revenue stream. The net income of 991,927 in the latest quarter suggests a positive trajectory towards profitability. However, liquidity remains a concern, with cash and cash equivalents reported at 271. Overall, Regen BioPharma, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in innovative therapeutic solutions.